Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Share-based Compensation (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Share-based Compensation for 9 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 72.02% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.0 million through Dec 2025, down 43.26% year-over-year, with the annual reading at $14.0 million for FY2025, 43.26% down from the prior year.
  • Share-based Compensation hit $1.7 million in Q4 2025 for Sutro Biopharma, up from $1.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.0 million in Q1 2022 to a low of $1.6 million in Q3 2025.
  • Historically, Share-based Compensation has averaged $5.7 million across 5 years, with a median of $6.0 million in 2023.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 123.1% in 2021 and later plummeted 76.29% in 2025.
  • Year by year, Share-based Compensation stood at $6.9 million in 2021, then fell by 15.03% to $5.9 million in 2022, then grew by 6.34% to $6.2 million in 2023, then fell by 4.95% to $5.9 million in 2024, then crashed by 72.02% to $1.7 million in 2025.
  • Business Quant data shows Share-based Compensation for STRO at $1.7 million in Q4 2025, $1.6 million in Q3 2025, and $5.3 million in Q2 2025.